MaxCyte will put your blood cells to work. Its cell-loading technologies use blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company partners with drugmakers to help them develop more effective therapies in a shorter amount of time. MaxCyte's partners have included biotech firms Geron, MediNet, and Northern Therapeutics. The company works to develop immune system therapies in a variety of fields, including oncology and cardiology. MaxCyte was founded in 1999.